The project delivery specialists



**QP Forum 2025 – Tuesday 13th May** 

# **Rewiring Pharma for the Digital age**

Addressing challenges in Annex 1

Presented by Alan Kelly Thursday 13<sup>th</sup> May 2025



# **Robotic Assisted Surgery**



Robotic assisted surgery first took place in March 1997 on a living patient using **Intuitive Surgicals** robot known as **Mona** 



**Intuitive Surgicals** carried out further technology advancements resulting in the FDA approval of the **da Vinci** system for general robotic surgery in 2000.

# **Regulatory Landscape**

EUROPEAN

COMMISSION

Brussels, 22.8.2022

C(2022) 5938 final



#### 2 Principle

2.1 The manufacture of sterile products is subject to special requirements in order to minimize risks of microbial, particulate and endotoxin/pyrogen contamination. The following key areas should be considered:

Facility, equipment and process should be appropriately designed, qualified and/or validated and where applicable, subjected to ongoing verification according to the relevant sections of the Good Manufacturing Practices (GMP) guidelines. <u>The use of appropriate technologies</u> (e.g. Restricted Access Barriers Systems (RABS), isolators, <u>robotic systems</u>, rapid/alternative methods and continuous monitoring systems) should be considered to increase the protection of the product from potential extraneous sources of <u>endotoxin/pyrogen</u>, particulate and microbial contamination such as personnel, materials and the surrounding environment, and assist in the rapid detection of potential contaminants in the environment and the product.

development of emerging manufacturing technology may lead to improved manufacturing, and therefore improved product quality and availability throughout a product's lifecycle.

Through this guidance, FDA hopes to facilitate the application of good science and modern

8.9 Where possible, the use of equipment such as RABS, isolators or other systems, should be considered in order to reduce the need for critical interventions into grade A and to minimize the risk of contamination. Robotics and automation of processes can also be considered to eliminate direct human critical interventions (e.g. dry heat tunnel, automated lyophilizer loading, sterilisation in place).

The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with *Heral Register*. -506-9136.

GUIDELINES

#### Contamination Control Strategies must have a Holistic Focus P **Contamination Control Strategy - Governance** GROUP Governance defined oversight and escalation Monitoring of Controls material environmental personal utility in-process pest monitoring monitoring monitoring monitoring monitoring control Validation of Controls Instead of measuring the facility, utility, equip. personal qual. analytical method process qual. Controls we need to & life cycle qual. & life cycle qual. & regual. & requal. Design/Build the Controls = Strategy ! If we neglect to run with **Contamination Controls** appropriate engineering facility & solutions at this stage – equipment training, utility material design, process this can have major hygiene, desian, design selection cleaning, gowning implications for cleaning, anitization

Personnel Awareness / Quality Culture

**Contamination Risk Assessment** 

Source: Rapid Micro Biosystems

sanitization

production and controls

following

## Regulatory Direction Annex 1

8.9

"Robotics and automation processes can also be considered to eliminate direct human interventions"

# 8.16

"Engineering solutions should be used where possible to minimise incursions by operators during the interventions" 4.4

"Direct interventions (e.g. without the protection of barrier and glove port technology) should be minimised by premises, equipment...."








Progress Aseptic Filling Industry

### The Start



Filling in rooms with **Humans** 



Increasing Systems Integrity



### Today




### Filling in gloveless isolators

# New family of Gloveless Isolator Technology













### **Progress but some limitations** Gloveless Isolator Technology



Gloveless technologies have moved the industry forward, but hurdles still remain...

#### **Air Flow**

Airflow/eddies due to space miniaturization.

### Interventions

Stop filling, retract product path, open doors and perform intervention, then perform H202 Cycle.

### **Grade A Space and Facility Contamination Control**

Risk as need to open isolator between batches to surrounding environment.

### **Tub Introduction Technology**

Use of (batch or semi-batch process, H202 residue issues) Tubs enter Grade A environment.

### **Environmental Monitoring**

Plate manipulation before production performed in a remote isolator with gloves. Plates introduced after H2O2 Cycle.

# Dare to achieve through collaboration



Thinking outside the box with collaboration at the heart





## Dare to achieve through collaboration



Brainstorm Ideas & Address Industry Challenges International Collaborative Approach

### Pharma Integration Robotic Filling Technologies

PM Group Process Technologies / Facility Integration



The sum is stronger than individual parts

# Azurramicro Azurrasmall Azurrafab

GROUP

# Pharma Integration



# 2016 > 2020

A company providing cutting-edge **robotic systems** dedicated to **small volume fill-finishing**.

Pharma Integration developed 1<sup>st</sup> commercial scale robotic filling platform with gloveless isolator.

# 2021 > Today

Further development of 1st robotic platform to create

Azzurra Platform Technology, working with industrial partners PM Group and PMS.



**R&D Module** 



GMP Isolated Filling Line in 4 Modules

# **Azurrafab**

# **Development of** Aseptic Filling Technology





Gloveless Isolators Automated Robot Line

# Collaboration with Regulators for Benefit of Industry

- Global Regulators want FASTER ADOPTION of beneficial innovative technologies.
- Workshop and review with Former MHRA Annex 1 specialist Alan Moon.
- 2023 Azzurra FAB invited onto FDA Emerging Technology Programme without a client sponsor...
- May 2024 ISPE "Companies that engage with ETT were significantly more successful at advancing their respective innovations than companies that did not"
- 2 Workshops with FDA ETT:
  - Jan and Sep 2024.
  - Overall very positive engagement and reports.
  - Modifications to design and testing as a result of some comments.



Regulators





# Azzurra fab Introduction




14

# Azzurrafab Facility Integration







- Enclosure with dedicated ventilation system (vertical LAF- Grade A air supply).
- VHP decontamination prior to production.
- **Blades** (for the cutting of the bag) are located **inside** the drawer (decontaminated).
- Full access (for cleaning) and visibility of the entire system at all stages of the process.

- Enhanced NTT with UV Decontamination.
- No human contact with the interior part of the bag.
- Tub not introduced into the critical area (inside the filling isolator).
- Transfer of bag to UV light is within 1 second with UV exposure in very close proximity.

# **Gloveless Environmental Monitoring**





### Collaboration with PMS Two innovative patents:

Single-Use EM Plate for active viable air sampling is designed for robotic manipulation.

Plate is placed before H202 cycle and handled entirely by the robot.

The Robotic Rotor accommodates 4 EM plates to be positioned at the same sampling point.








# Dare to Believe Next Generation Robotic Filling Platform






Fully robotized aseptic filling technology platform to support clinical and commercial. A standardized and modular design and construction. Overcomes many of existing industry challenges. Part of FDA Emerging Technology Programme. A more collaborative approach, providing a more holistic DP Facility solution.

# Going back to the future











# **Questions?**



# Thanks for your time today.

For more information please visit www.pmgroup-global.com



# Azurra an Technical Details





### Azzurra fab

Dimensions	8180 x 2370 x 2900 mm		
Application	Vials, syringes and cartridges both RTU & bulk		
Closure type	Any type – both bulk and nested		
Product type	Liquid/Iyo and powder		
Output	3000 containers/h		
Robotic system	8 Denso 6-axes robots		
Decontamination Cycle	< 60 minutes		
Downtime between batche	4 h		

Pharma Integration operates (PI) independently from PM Group.

Azzurra Platform is marketed solely by Pl.

PM Group remains independent of PI in its recommendations, whilst acknowledging our investment and close relationship with PI.

# Portfolio **Technical details**





### Azzurramicro

0.52				
	1			
	 Cumu	, ann	Juun	10113

Vials, syringes and cartridges both RTU & bulk

### Azzurrasmall

6700 x 1800 x 2700 mm

Uguid/fyo and powder

8 Denso 6-axes robots

3000 containers/h

< 60 minutes

4 h

Any type - both bulk and nested



### Azzurrafab

8180 x 2370 x 2900 mm	
Vials, syringes and carbridges both RTU & bulk	
Any type - both bulk and nested	
Liquid/lyo and powder	
3000 containers/h	
8 Denso 6-aves robots	
< 60 minutes	
4 h	



Dimensions	
Application	
Closure type	
Product type	
Output	
Robotic system	
Decontamination Cycle	

Downtime between batches

3800 x 1800 x 2300 mm Vials, syringes & cartridges both RTU & bulk Any type - both bulk and nested Liquid/fyo and powder 900 containers/h 4 Denso 6-axes robots < 30 minutes 2h

Technical details are purely indicative and may be subject to changes without prior notice

# Azurrafab Main Features

Modularised & Standard Design.

Room Isolator.

Butler robots interfacing with VHP Pass Box and RTP.

Monoblock allowing for pre-testing in Factory and simple Plug and Play installation leading to quicker installation and start-up times.

Able to accommodate wide variety of components – Vials/ Syringes /Cartridges / Double Chamber / Push-fit. Designed for High potency including ability to externally wash/dry vials prior to re-nesting. Annex 1 Compliant including Fully robotic, First Air, EM Monitoring, Aseptic Surface Monitoring (FAB), designed to support CCS.

GROUP

**Patented Technology** 

NTT & UV-C Decontamination for Tub Introduction.

EM & Plate Technology.

Butler robot.

Azzurra platform shape genuinely adhering to First Air principles.

### For the AzzurraFAB

Ability to perform longer batches and campaign working using VHP P/Ts and butler robots.

Critical areas protected to surrounding environments via A/Ls.

Butler and process robots to perform interventions.

\*Technology patents are either shared between PM and PI or belong to PI